Your browser doesn't support javascript.
loading
Emerging technologies and their impact on regulatory science.
Anklam, Elke; Bahl, Martin Iain; Ball, Robert; Beger, Richard D; Cohen, Jonathan; Fitzpatrick, Suzanne; Girard, Philippe; Halamoda-Kenzaoui, Blanka; Hinton, Denise; Hirose, Akihiko; Hoeveler, Arnd; Honma, Masamitsu; Hugas, Marta; Ishida, Seichi; Kass, George En; Kojima, Hajime; Krefting, Ira; Liachenko, Serguei; Liu, Yan; Masters, Shane; Marx, Uwe; McCarthy, Timothy; Mercer, Tim; Patri, Anil; Pelaez, Carmen; Pirmohamed, Munir; Platz, Stefan; Ribeiro, Alexandre Js; Rodricks, Joseph V; Rusyn, Ivan; Salek, Reza M; Schoonjans, Reinhilde; Silva, Primal; Svendsen, Clive N; Sumner, Susan; Sung, Kyung; Tagle, Danilo; Tong, Li; Tong, Weida; Eijnden-van-Raaij, Janny van den; Vary, Neil; Wang, Tao; Waterton, John; Wang, May; Wen, Hairuo; Wishart, David; Yuan, Yinyin; Slikker, William.
Afiliação
  • Anklam E; Joint Research Centre, EU.
  • Bahl MI; National Food Institute, Technical University, Denmark.
  • Ball R; U.S. Food and Drug Administration.
  • Beger RD; U.S. Food and Drug Administration.
  • Cohen J; U.S. Food and Drug Administration.
  • Fitzpatrick S; U.S. Food and Drug Administration.
  • Girard P; Swissmedic, Switzerland.
  • Halamoda-Kenzaoui B; Joint Research Centre, EU.
  • Hinton D; U.S. Food and Drug Administration.
  • Hirose A; National Institute of Health Sciences, Japan.
  • Hoeveler A; Joint Research Centre, EU.
  • Honma M; National Institute of Health Sciences, Japan.
  • Hugas M; European Food Safety Authority, EU.
  • Ishida S; National Institute of Health Sciences, Japan.
  • Kass GE; European Food Safety Authority, EU.
  • Kojima H; National Institute of Health Sciences, Japan.
  • Krefting I; U.S. Food and Drug Administration.
  • Liachenko S; U.S. Food and Drug Administration.
  • Liu Y; Median Technologies, France.
  • Masters S; U.S. Food and Drug Administration.
  • Marx U; TissUse, Germany.
  • McCarthy T; Pfizer, USA.
  • Mercer T; Garvan Institute, Australia.
  • Patri A; U.S. Food and Drug Administration.
  • Pelaez C; Spanish Council for Scientific Research, Spain.
  • Pirmohamed M; University of Liverpool, UK.
  • Platz S; AstraZeneca, UK.
  • Ribeiro AJ; U.S. Food and Drug Administration.
  • Rodricks JV; Ramboll, USA.
  • Rusyn I; Texas A&M University, USA.
  • Salek RM; International Agency for Research on Cancer, France.
  • Schoonjans R; European Food Safety Authority, EU.
  • Silva P; Canadian Food Inspection Agency, Canada.
  • Svendsen CN; Cedars-Sinai Medical Center, USA.
  • Sumner S; University of North Carolina, Chapel Hill, USA.
  • Sung K; U.S. Food and Drug Administration.
  • Tagle D; National Institutes of Health, USA.
  • Tong L; Universities of Georgia Tech and Emory, USA.
  • Tong W; U.S. Food and Drug Administration.
  • Eijnden-van-Raaij JVD; Dutch Organ-on-Chip Consortium, The Netherlands.
  • Vary N; Canadian Food Inspection Agency, Canada.
  • Wang T; National Medical Products Administration, China.
  • Waterton J; University of Manchester and Bioxydyn Ltd, UK.
  • Wang M; Universities of Georgia Tech and Emory, USA.
  • Wen H; National Institutes for Food and Drug Control, China.
  • Wishart D; University of Alberta, Canada.
  • Yuan Y; The Institute of Cancer Research, UK.
  • Slikker W; U.S. Food and Drug Administration.
Exp Biol Med (Maywood) ; 247(1): 1-75, 2022 01.
Article em En | MEDLINE | ID: mdl-34783606
ABSTRACT
There is an evolution and increasing need for the utilization of emerging cellular, molecular and in silico technologies and novel approaches for safety assessment of food, drugs, and personal care products. Convergence of these emerging technologies is also enabling rapid advances and approaches that may impact regulatory decisions and approvals. Although the development of emerging technologies may allow rapid advances in regulatory decision making, there is concern that these new technologies have not been thoroughly evaluated to determine if they are ready for regulatory application, singularly or in combinations. The magnitude of these combined technical advances may outpace the ability to assess fit for purpose and to allow routine application of these new methods for regulatory purposes. There is a need to develop strategies to evaluate the new technologies to determine which ones are ready for regulatory use. The opportunity to apply these potentially faster, more accurate, and cost-effective approaches remains an important goal to facilitate their incorporation into regulatory use. However, without a clear strategy to evaluate emerging technologies rapidly and appropriately, the value of these efforts may go unrecognized or may take longer. It is important for the regulatory science field to keep up with the research in these technically advanced areas and to understand the science behind these new approaches. The regulatory field must understand the critical quality attributes of these novel approaches and learn from each other's experience so that workforces can be trained to prepare for emerging global regulatory challenges. Moreover, it is essential that the regulatory community must work with the technology developers to harness collective capabilities towards developing a strategy for evaluation of these new and novel assessment tools.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Simulação por Computador / Pesquisa Biomédica Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Exp Biol Med (Maywood) Assunto da revista: BIOLOGIA / FISIOLOGIA / MEDICINA Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Simulação por Computador / Pesquisa Biomédica Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Exp Biol Med (Maywood) Assunto da revista: BIOLOGIA / FISIOLOGIA / MEDICINA Ano de publicação: 2022 Tipo de documento: Article